{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:38:25Z","timestamp":1784039905256,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clon.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,25]],"date-time":"2017-10-25T09:32:37Z","timestamp":1508923957000},"page":"778-786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6935-3232","authenticated-orcid":false,"given":"C.","family":"Gilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-1371","authenticated-orcid":false,"given":"M.R.","family":"Sydes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clon.2017.10.004_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.clon.2017.10.004_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clon.2017.10.004_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clon.2017.10.004_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2017.10.004_bib5","unstructured":"Cancer Research UK. Cancer Research UK Biomarker Roadmap Sept-09\u20132017. Available from: http:\/\/www.cancerresearchuk.org\/prod_consump\/groups\/cr_common\/@fre\/@fun\/documents\/generalcontent\/cr_027486.pdf."},{"issue":"5","key":"10.1016\/j.clon.2017.10.004_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.clon.2017.10.004_bib7","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clon.2017.10.004_bib8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur Urol"},{"issue":"7406","key":"10.1016\/j.clon.2017.10.004_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"7547","key":"10.1016\/j.clon.2017.10.004_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clon.2017.10.004_bib11","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.clon.2017.10.004_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clon.2016.04.047","article-title":"Ten years on the juggernaut keeps on rolling: comments on the STAMPEDE trial from the front line","volume":"28","author":"Birtle","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clon.2017.10.004_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1745-6215-10-39","article-title":"Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial","volume":"10","author":"Sydes","year":"2009","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.clon.2017.10.004_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clon.2017.10.004_bib15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bju.13400","article-title":"Will chemotherapy change the management of prostate cancer?","volume":"118","author":"Gilson","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clon.2017.10.004_bib16","series-title":"Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476)","author":"Sydes","year":"2017"},{"issue":"6","key":"10.1016\/j.clon.2017.10.004_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.eururo.2016.07.015","article-title":"Repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform","volume":"70","author":"Gillessen","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clon.2017.10.004_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.urolonc.2012.08.016","article-title":"Use of transdermal estrogen in the management of advanced prostate cancer","volume":"31","author":"Cafferty","year":"2013","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.clon.2017.10.004_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clon.2017.10.004_bib20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.eururo.2015.11.030","article-title":"A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol","volume":"69","author":"Langley","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clon.2017.10.004_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bju.13687","article-title":"Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","volume":"119","author":"Gilbert","year":"2017","journal-title":"BJU Int"},{"issue":"17","key":"10.1016\/j.clon.2017.10.004_bib22","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2011.1605","article-title":"Detours on the road to personalized medicine: barriers to biomarker validation and implementation","volume":"306","author":"Fiore","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2017.10.004_bib23","series-title":"Transforming pathology & diagnostic practice","author":"Genomic England","year":"2017"},{"issue":"14","key":"10.1016\/j.clon.2017.10.004_bib24","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2017.10.004_bib25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.clon.2017.10.004_bib26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clon.2017.10.004_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"36","key":"10.1016\/j.clon.2017.10.004_bib28","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2013.50.7905","article-title":"Evaluating many treatments and biomarkers in oncology: a new design","volume":"31","author":"Kaplan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2017.10.004_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.clon.2017.10.004_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.clon.2017.10.004_bib31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clon.2017.10.004_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clon.2017.10.004_bib33","series-title":"PROREPAIR-B: a prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer","author":"Castro","year":"2017"},{"issue":"14","key":"10.1016\/j.clon.2017.10.004_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pros.23219","article-title":"A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling","volume":"76","author":"Cheng","year":"2016","journal-title":"Prostate"},{"issue":"15_suppl","key":"10.1016\/j.clon.2017.10.004_bib35","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2017.35.15_suppl.5001","article-title":"Abiraterone + prednisone (Abi) +\/\u2212 veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data","volume":"35","author":"Hussain","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2017.10.004_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clon.2017.10.004_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clon.2017.10.004_bib38","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nsmb.1915","article-title":"Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination","volume":"17","author":"Buisson","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"12","key":"10.1016\/j.clon.2017.10.004_bib39","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.dnarep.2008.08.014","article-title":"A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity","volume":"7","author":"Lord","year":"2008","journal-title":"DNA Repair (Amst)"},{"issue":"16","key":"10.1016\/j.clon.2017.10.004_bib40","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2017.10.004_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2013.218","article-title":"Biomarker enrichment strategies: matching trial design to biomarker credentials","volume":"11","author":"Freidlin","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2017.10.004_bib42","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clon.2017.10.004_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clon.2017.10.004_bib44","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clon.2017.10.004_bib45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2017.10.004_bib46","series-title":"ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)","author":"Ledermann","year":"2017"},{"issue":"7391","key":"10.1016\/j.clon.2017.10.004_bib47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/483519a","article-title":"Drug candidates derailed in case of mistaken identity","volume":"483","author":"Ledford","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.clon.2017.10.004_bib48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/annonc\/mdu478","article-title":"Prioritizing targets for precision cancer medicine","volume":"25","author":"Andre","year":"2014","journal-title":"Ann Oncol"},{"issue":"7387","key":"10.1016\/j.clon.2017.10.004_bib49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clon.2017.10.004_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clon.2017.10.004_bib51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13059-014-0453-8","article-title":"Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine","volume":"15","author":"Hiley","year":"2014","journal-title":"Genome Biol"},{"issue":"Suppl 6","key":"10.1016\/j.clon.2017.10.004_bib52","doi-asserted-by":"crossref","first-page":"s33","DOI":"10.7861\/clinmedicine.14-6-s33","article-title":"Spatial and temporal cancer evolution: causes and consequences of tumour diversity","volume":"14","author":"Hiley","year":"2014","journal-title":"Clin Med (Lond)"},{"issue":"3","key":"10.1016\/j.clon.2017.10.004_bib53","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.13121782","article-title":"Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer\u2013factors affecting diagnostic success","volume":"269","author":"Spritzer","year":"2013","journal-title":"Radiology"},{"issue":"15","key":"10.1016\/j.clon.2017.10.004_bib54","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1158\/1078-0432.CCR-14-3136","article-title":"Analyses of 7,635 patients with colorectal cancer using independent training and validation cohorts show that rs9929218 in CDH1 is a prognostic marker of survival","volume":"21","author":"Smith","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.clon.2017.10.004_bib55","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-2581","article-title":"Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +\/\u2212 cetuximab","volume":"19","author":"Smith","year":"2013","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655517304387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655517304387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:44:00Z","timestamp":1760543040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655517304387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0936655517304387"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2017.10.004","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}